Original Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Jul 7, 2012; 18(25): 3215-3222
Published online Jul 7, 2012. doi: 10.3748/wjg.v18.i25.3215
Figure 2
Figure 2 Baseline and follow-up images after treatment of fluorodeoxyglucose uptake according to the Tsuvmax/Lsuvmean ratio. A: Patient with nodular hepatocellular carcinoma (HCC) (white arrow) based on liver dynamic computed tomography (CT) showed fluorodeoxyglucose (FDG) uptake with a low Tsuvmax/Lsuvmean ratio (< 1.90) in 18F-FDG positron emission tomography/CT. After transarterial chemo embolization, this patient showed compact lipiodol uptake (red arrow) on follow-up liver CT; B: Patient with infiltrative type HCC (white arrow) in liver dynamic CT showed FDG uptake with a high Tsuvmax/Lsuvmean ratio (≥ 1.90). This patient showed faint lipiodol uptake (red arrow) in a follow-up liver CT. The patent with a low standardized uptake value (SUV) ratio showed improved treatment response and survival over the patient with a high SUV ratio (complete response vs stable disease, 782 d vs 167 d, respectively).